Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.
about
Pharmacokinetics of carumonam (AMA-1080) in patients with impaired renal function and in those undergoing hemodialysis.Effect of haemodialysis on metoclopramide kinetics in patients with severe renal failure.Didanosine pharmacokinetics in patients with normal and impaired renal function: influence of hemodialysis.Disposition of didanosine in HIV-seropositive patients with normal renal function or chronic renal failure: influence of hemodialysis and continuous ambulatory peritoneal dialysis.Disposition of cefmetazole in healthy volunteers and patients with impaired renal function.Hemodialysis clearance of metronidazole and its metabolites.Removal of imipenem and cilastatin by hemodialysis in patients with end-stage renal failureDesign, conduct, analysis, and interpretation of clinical studies in patients with impaired kidney function.The pharmacokinetics and extracorporeal removal of N-acetylcysteine during renal replacement therapies.Pharmacokinetics of intravenous, single-dose tiotropium in subjects with different degrees of renal impairment.Irinotecan in cancer patients with end-stage renal failure.Meropenem and continuous renal replacement therapy: in vitro permeability of 2 continuous renal replacement therapy membranes and influence of patient renal function on the pharmacokinetics in critically ill patients.Evaluation and first validation study on a simplified drug dosage algorithm for multiple organ failure patients.Pharmacokinetics and protein binding of eprosartan in hemodialysis-dependent patients with end-stage renal disease.
P2860
Q33743463-94270227-43AD-4050-A3DE-224B546A4443Q34418135-279712A4-97D7-4452-911F-F2C96E707DB7Q34547322-40408C92-C278-4CEA-8994-5E6C6C39C350Q34736674-A6AE459E-249D-4A16-9B65-3D8F0C8F9DC3Q35251699-C0D37014-EAD3-4872-A63A-2B3332FD7DB0Q35573211-DCF3764C-EF54-44CE-92E9-21FFAAA7B720Q36754535-84D3B37E-9FD0-4364-9125-132469B0C92CQ39664155-37DAF9D7-568B-4141-A685-7EE9AF1DDD3BQ40411121-6C24AFC2-0ABB-43EE-A5BA-9A49D0CC8D50Q44745258-1CB9BCFC-2A41-4BDC-95EF-33DD35934054Q46133392-EE2FE502-8D9A-4DF7-A4AE-C4DAAED44B47Q46766008-6E6EC062-B660-48DA-9411-92F94EDBCA3CQ52433041-E05F4FF6-3DF2-4DD2-9491-2954D1F239D7Q53932043-CF6A9F05-8457-4B0C-8F79-28667C2BCE24
P2860
Drug therapy in patients undergoing haemodialysis. Clinical pharmacokinetic considerations.
description
1984 nî lūn-bûn
@nan
1984年の論文
@ja
1984年論文
@yue
1984年論文
@zh-hant
1984年論文
@zh-hk
1984年論文
@zh-mo
1984年論文
@zh-tw
1984年论文
@wuu
1984年论文
@zh
1984年论文
@zh-cn
name
Drug therapy in patients under ...... harmacokinetic considerations.
@en
type
label
Drug therapy in patients under ...... harmacokinetic considerations.
@en
prefLabel
Drug therapy in patients under ...... harmacokinetic considerations.
@en
P1476
Drug therapy in patients under ...... harmacokinetic considerations.
@en
P2093
P356
10.2165/00003088-198409010-00003
P577
1984-01-01T00:00:00Z
P6179
1032105808